• Company has, to date, raised $41.5 million and has more than 2,400 shareholders
• Has one of the largest licensed land parcels in Canada, situated on 100 acres
• Offers organically grown, pesticide-free medical marijuana under Canada’s ACMPR

The Green Organic Dutchman Holdings Ltd. (“TGOD”), a Canadian company engaged in producing farm-grown, high-quality organic medical cannabis using craft growing, all natural, organic principles, announced on September 11 (http://dtn.fm/8GkWq) that it has entered into an agreement with a syndicate led by PI Financial Corp. to complete a private placement offering of units. The syndicate will offer, on a commercially reasonable effort basis, 4,242,500 units of the company at an issue price of C$1.65 per unit for aggregate gross proceeds of C$7,000,125.

TGOD will also concurrently engage in a non-brokered offering of 7,879,000 units, with each unit being offered at C$1.65 for aggregate gross proceeds of $13,000,350, under the same terms as the unit offering.

Each unit will consist of one common share of TGOD and one-half common share purchase warrant of the company. Each whole warrant is exercisable into one common share at the exercise price of $3.00 per share and has an expiration date that is either 36 months from the date the common shares begin trading on a recognized stock exchange or February 28, 2021, whichever is earlier.

TGOD plans to use the net proceeds of the unit offering and the non-brokered offering to advance its cannabis facilities in Ontario and Quebec, as well as for general working capital purposes.

A private producer of high-grade, organically grown and pesticide-free medical cannabis under the ACMPR, TGOD grows its marijuana in small batches, and its products are laboratory tested to ensure all recipient patients are provided with a standardized, safe and consistent product.

TGOD has a funded capacity of 14,000 kg and has one of the biggest licensed land parcels in Canada, situated on 100 acres. The company also recently secured a second 75-acre, fully serviced site near Montreal and is currently in the process of expanding its cultivation capacity to 116,000 kg and increasing its product offerings preparatory to recreational cannabis use becoming federally legal in Canada in 2018—something the Canadian government is currently making strides toward.

To date, TGOD has raised $41.5 million and has more than 2,400 shareholders.

For more information, visit the company’s website at www.TGOD.ca

• Producer of consistent, standardized medicinal cannabis
• Menu of cannabis strains with varying CBD:THC ratios
• ABcann’s CBD-Med is one of Canada’s highest-CBD products

In an interview with Cantech Letter (http://dtn.fm/5Deu5), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis for pain relief or other medical purposes, this was causing a great deal of concern.

Inconsistency in product quality makes the determination of optimal dosage levels impossible to achieve. As a result, “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on” became one of ABcann’s founding principles. That principle continues to guide the company to this day. The Canadian-licensed producer recently announced the release of one of Canada’s highest legal CBD:THC ratio cannabis products. This new product expands the range of therapies now available to patients and so increases the efficacy of current treatment regimens in the promising new field of cannabinoid therapies.

At present, the majority of cannabinoid therapies are directed to alleviate the chronic pain resulting from a variety of maladies. Since delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the cannabinoids occurring at the highest concentrations in cannabis, the therapeutic effects of the plant and its derivatives are most likely derived from these components acting alone or together.

This is a line of research that has been explored successfully by GW Pharmaceuticals. The European company produces Sativex, a treatment for the relief of symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS), which contains a one-to-one ratio of THC to CBD. While many patients have found relief from pain in high-THC cannabis, a subset of these have reported short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks. Fortunately, CBD is devoid of such malignant manifestations, exhibiting calming and uplifting properties that appear to mitigate the unwanted effects of THC. As a result, strains of cannabis that are rich in CBD, like those produced by ABcann, are most helpful to those averse or intolerant to THC and to patients who want pain relief without too much of a ‘high’.

A look at the stats released by Health Canada will show where ABcann is on the CBD:THC ratio spectrum. Most cannabis strains (54%) on the Canadian market have a high CBD:THC ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD under 1%. Only 14% of strains have both THC and CBD levels that exceed 5%, and just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which the latest ABcann strains can be found.

Late last month, the company announced (http://dtn.fm/bAJw6) the release of its top-of-the-line CBD-Med, which has a ratio of 27.6:1 (18.5% CBD to 0.67% THC). This adds to ABcann current lineup of high-CBD products, which already include NC:Med, with 18.9% CBD to 1% THC and DC:Med, with 15.4% CBD to 1% THC. ABcann also expects to be able to sell oils from October 2017, a range that will include a 1:1 THC/CBD drop, a high THC dropper and a high CBD dropper.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board

• Greenkraft, Inc. expects to realize well over $1 million of new revenue in 2017
• Expansion plans include construction of larger manufacturing facility to accommodate increasing demand for Greenkraft’s alternative fuel commercial trucks
• A new line of larger, heavy duty G3 and G4 commercial trucks are coming soon
• Greenkraft vehicles meet EPA and CARB emission standards through use of clean alternative fuels

Greenkraft, Inc. (OTCQB: GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company’s mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft’s new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

“Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel,” Gemayel states in a press release. “The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company’s revenue in 2017.”

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client’s specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation’s largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners.

For more information, visit the company’s website at www.GreenkraftInc.com

Let us hear your thoughts: Greenkraft, Inc. Message Board

• IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease
• Company has a first-mover advantage in phytocannabinoid-based combination therapy
• Alzheimer’s is America’s most expensive disease, costing the country an estimated $259 billion in 2017

It is considered America’s most expensive disease, projected to cost an estimated $259 billion in the United States in 2017 and as much as $1.1 trillion by 2050 (http://dtn.fm/2UWLl). It is not cancer, and it is not AIDS. It is Alzheimer’s disease.

This devastating chronic neurodegenerative disease is the most common cause of dementia among older adults and is the sixth-leading cause of death in the U.S. There is currently no cure for Alzheimer’s disease, nor are there presently any effective treatments to slow the disease or reverse its effects, but India Globalization Capital, Inc. (NYSE MKT: IGC) is working to change that.

In a recent press release (http://dtn.fm/5qvM2), IGC discussed its progress on IGC-ADI, a drug candidate that is cannabis-based and targeted at lessening some of Alzheimer’s worst symptoms. IGC-ADI works through a molecular pathway that permits low doses of tetrahydrocannabinol (THC) to do five things:

1. Inhibit Aβ protein production
2. Inhibit Aβ protein aggregation
3. Reduce protein phosphorylation
4. Restore mitochondria function
5. Redirect the immune system

Amyloid beta peptide (Aβ) is a protein believed to cause the formation of plaque in the cerebral cortex and hippocampus, causing lesions. Alzheimer’s disease is believed to be caused by two different types of lesions—the first being senile plaque that is made up of amyloid beta peptides (Aβ plaque) and the second being neurofibrillary tangle, which is composed of highly phosphorylated Tau protein.

Aβ proteins are normally cleared away through biological processes, but, in Alzheimer’s patients, these proteins are unregulated and build up into insoluble fibroles. Senile plaques and extracellular misfolded oligomers resultantly form and are believed to be toxic to nerve cells in the brain. It has been found that IGC-AD1 may inhibit the production of amyloid beta peptide.

In a recent press release, IGC provided an update on in vitro data compiled from genetically engineered cell lines, which has been confirmed by IGC Senior Advisor Dr. Chuanhai Cao, who is also an associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. The data shows that at varying THC concentrations, production of Aβ40 protein decreases by as much as 50 percent over a 48-hour time period.

Aβ40 and Aβ42 play a central role in amyloid plaques and have been implicated in the pathogenesis of Alzheimer’s disease. Dr. Cao’s studies at USF led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC has since acquired the exclusive rights to the patent filing, and the company intends to advance the technology through medical trials, with the ultimate aim of bringing relief to Alzheimer’s sufferers.

IGC is currently the only publicly traded cannabis stock to have patent filings for a potential breakthrough Alzheimer’s treatment. This gives the company a first-mover advantage in phytocannabinoid-based combination therapy, as discussed in a recently published article featuring IGC and four other standout companies that are currently seeking to find viable treatments for Alzheimer’s (http://dtn.fm/9YfF0).

For more information, visit the company’s website at www.IGCInc.us

• Acquisition of Contractor Exam Preps of Pittsboro, North Carolina, would give One Exam Prep access to new markets, customers
• One Exam Prep is already on pace to have 70% gain in year-over-year revenues
• Chris Barrow, president of Contractor Exam Preps, would join One Exam Prep division as a master instructor

ProBility Media Corp. (OTCQB: PBYA), through its One Exam Prep division, has entered into an asset purchase agreement (http://dtn.fm/S5fHx) with Contractor Exam Preps of Pittsboro, North Carolina. The acquisition would expand One Exam Prep’s markets and customers.

ProBility Media is an EdTech company which offers the skilled trades high quality training courses, eLearning opportunities and materials. The firm is seeking to build an international brand for educating, training and compliance for the skilled trades. It serves small businesses, as well as enterprise-level corporations.

In a news release, Noah Davis, president and COO of ProBility, said, “With sales on pace to exceed a 70% increase year-over-year, combined with the anticipated addition of Contractor Exam Preps, One Exam Prep is poised to enter new markets and offer more to its current and new customers than ever before.”

Chris Barrow, president of 20-year-old Contractor Exam Preps, would join One Exam Prep as a master instructor, per the purchase agreement. “We are very much looking forward to integrating Barrow’s expertise and skill sets into One Exam Prep,” said Rob Estell, founder and president of One Exam Prep. “We currently service 22 states and offer hundreds of high-quality online courses, private e-tutoring, application processing, daily physical classes, and all of the training materials, at very competitive pricing.”

Employer-based formal training in the U.S. is a $177 billion annual market, according to a ProBility presentation within an 8K SEC filing (http://dtn.fm/nO34q). The Trump administration’s infrastructure plans call for an increase in apprenticeships to five million from 40,000 today. Some 60% of the jobs created by the $1 trillion plan will require less than six months of training.

ProBility offers educational and compliance materials for 60 skilled trades in 15 categories. The diverse list of subjects includes electrical, solar, glass glazing, plumbing, air conditioning, irrigation, pollutant storage, and others. It is targeting annual organic revenue growth of 25-30% and 20-25% additional sales through acquisitions, the presentation shows. Further, it is targeting a 30% EBITDA margin.

For more information, visit the company’s website at www.ProBilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

• HighCom’s blast protection products are ISO 9001:2008 certified and meet the quality standards of BA 9000
• The company has manufactured over a million plates with no operational failures or recalls
• In Q2 2017, it reported a 116 percent increase in year-over-year revenues, with $1.5 million earned over a three-month period

HighCom Global Security, Inc. (OTC: HCGS), a leader in blast effects mitigation solutions, has introduced several new products in 2017, while continuing to uphold its ISO 9001:2008-certified Quality Management System. This system has been in place since 2005 and was certified the following year. It helps assure approval of all products by the International Organization for Standardization (ISO). HighCom works to meet the basic requirements and continually make improvements. Its plates, helmets, shields, and other types of armor; bullet proof vests; ballistic blankets; and other offerings also adhere to the armor quality standards of BA 9000 certification, established by the National Institute of Justice (NIJ).

The company serves law enforcement, military and government customers, as well as those in the commercial sector. It can offer fire suppression for naval vessels and merchant ships. Products are also available to help protect buildings against vehicle-delivered bombs. In addition, the company supplies a line of rifle armor, civilian armor systems, vest attachments, and bags and pouches.

Just this year, several new products were introduced, including a lightweight and high-performance soft armor panel (the Level IIIa elite) and multi-curve, hard armor ballistic plate (the Level III++). Four new hard armor products were added in February, which have been recognized by the NIJ’s Compliance Testing Program. In terms of body armor, it is the only standard that has been nationally accepted. HighCom’s total of 11 hard armor and five soft armor solutions are certified to the institute’s high quality standards.

Since its founding in February 1997, the company has served a large and diverse market. Over about a decade, it distributed nearly one million pieces of ballistic armor via Department of Defense contracts, and it has capacity to output more than 20,000 pieces of armor each month. This high level of performance doesn’t seem to be slowing down. In a recent news release (http://dtn.fm/Xn5iD), HighCom Global Security reported a year-over-year increase of 116 percent for Q2 revenues. The company reported revenue of $1.5 million for the quarter, and $2.6 million for the first half of the year, which marked a 37.5 percent increase over the first half of 2016.

Its continued success is in part due to an ability to serve the global defense market and adhere to leading standards, but HighCom’s own technical development strategy also plays a role. A ballistic testing laboratory at the company’s Columbus, Ohio R&D center and manufacturing plant is where soft body armor, shields, tactical armor systems, helmets, and other products are developed and quality controlled. Here, testing guarantees 100 percent effectiveness, according to the company, and includes the same tests conducted at NIJ-approved ballistic labs worldwide.

For more information, visit the company’s website at www.HighComGlobal.com

Let us hear your thoughts: HighCom Global Security, Inc. Message Board

• ProBility now offers leading vocational educational materials in 60+ fields, including the electrical, construction, plumbing and security industries
• An overwhelming majority of technical employers are struggling to find workers with the appropriate skills
• Technical high schools are simulating workplaces to prepare students for their careers in historically underprivileged areas

Access to technology-based education resources is becoming open to more people. Even as the National Center for Education Statistics reported about 20.5 million students (fall 2016) were enrolled in colleges and universities throughout the U.S., career training and advancement materials are becoming more available to those looking for jobs requiring skilled labor. ProBility Media Corp. (OTCQB: PBYA) is a growing brand serving the training requirements for several different technical fields. In many of these, 95 percent of employers are having trouble finding workers with the right skills in 2017, based on U.S. Chamber of Commerce data published in a recent report (http://dtn.fm/5JQKg) on skilled labor demand.

Thanks to several recent acquisitions, ProBility can now provide study materials for electricians, construction workers, contractors, and plumbers, as well as many other skilled trades. The company provides access to all the latest NEC National Electrical Codes, with books, reference guides, and digital media available on CD and DVD. It has also reached into the public safety market. The launch of ProBility Safety Academy means training is open to those looking to advance their potential in public safety, private security, criminal justice, and police science.

The need for vocational training services is reaching from coast to coast. High school teachers and students alike are benefiting. In fact, technical high schools are cropping up in places like Huntington, West Virginia, as a recent New York Times article pointed out (http://dtn.fm/BOQ8g). Four teachers at a summer training program worked on a miniature boiler similar to larger counterparts found at power generating plants. The educational programs they’re preparing for will simulate workplaces and include everything from vocational training to random drug testing, to get students familiarized with work environments and prepared for future careers.

Simulated workplaces also have real-world equipment, ranging from drafting tables and welding torches to stethoscopes and 3D printers. Laser engraving equipment and professional software are expected to be used, from leading brands like AutoDesk Inventor. As part of the program, students will also get breaks during the day as employees working for technical organizations do.

ProBility is focused on providing a one-stop resource. Therefore, small- and medium-sized businesses can access e-learning resources, so they can offer employees training and career advancement opportunities. Its efforts to provide a single source of training materials does not stop at the borders of the United States. The recent acquisition of Cranbury International extends the company’s e-learning reach into the Caribbean, Mexico, Columbia, Brazil, and other countries in Central and South America.

For more information, visit the company’s website at www.ProbilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

• In FY2017, the company’s investor relations business grew 130%, and its subscriptions business rose by 57%
• Warren Wang, founder and chief executive officer of CIIX, sets goal of greater than 100% gain in sales in FY2018 and cost-cutting to achieve profitability
• Company excited about its expansion of auxiliary services into the digital currency industry; Wang says that market will offer long-term opportunities

ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded a skyrocketing 76% year-over-year operating revenues increase for its fiscal year ended May 31, 2017. The company’s two divisions exhibited double-digit and triple-digit growth in FY2017. The investor relations business grew 130%, while the subscriptions business rose 57% during the 2017 fiscal year, the company reported (http://dtn.fm/wLt1F). Total sales grew to $1,667,977 in FY2017 compared to $948,385 the prior year.

Warren Wang, founder and chief executive officer of CIIX, says the company’s goal is more than a 100% jump in FY2018 sales, while cutting costs and achieving profitability.

The primary reason for the increase in sales for the two divisions was a decision by management to be more discerning in deciding which companies would receive its investor relations services. Also, the firm placed itself on a more cash compensation basis — resulting in more sales — rather than taking equity compensation.

CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. It is focused on the R&D and distribution of legalized, hemp-based cannabidiol (CBD) to the global Chinese-speaking community. It maintains an online store in the free trade zone of Shanghai, China, and plans on opening a brick-and-mortar outlet in San Gabriel, California.

Before the end of 2017, CIIX plans to launch a cryptocurrency education and trading subscription service and the first Chinese daily video news broadcast from the NYSE covering digital currency and blockchain technology. It has also established CBD Biotechnology Co., Ltd., as a wholly-owned subsidiary in Shanghai, China. It launched OptHemp, its first hemp oil product line. In the coming months, the company said, it will unveil in China its first hemp-infused skin care product line.

“I am very pleased about the Company’s significant increase in revenue in the fiscal year ended May 31, 2017,” Warren Wang, founder and chief executive officer of CIIX, stated in a news release. “Although the blueprint of our Company’s business strategy has expanded through its entrance into the Hemp Industry, our core subscription and investors relations services remain strong with significant growth rates. I am thankful for the investors who have supported our ongoing development plans and look forward to a prosperous year ahead.”

For its non-industrial hemp-based products, the company has engaged Scottsdale, Arizona-based Launch Haus LLC to help it in its direct response marketing, digital, e-commerce and direct sales channels.

In addition, the company has thus far realized $2 million through August 29, 2017, from its private placement of some 10 million shares of its Series D-2017 convertible preferred stock, priced at $1 per share.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• SWRM restructures as one company with two divisions, capitalizing on synergies between MediaPlay and Incubation and Acquisition Development
• Ron Brewer, CEO and director, forecasts significant revenue growth in FY2017, cites strong initial revenues in FY2016
• New management team at SWRM, with extensive acquisition experience, is seasoned in growing emerging companies

AppSwarm, Inc. (OTC: SWRM), under its new management team, has restructured as one company split into two divisions, and management hopes to achieve revenues of $6-7 million by FY2018, Ron Brewer, the company’s CEO and director, noted in a recent news interview (http://dtn.fm/6Wu2I).

AppSwarm is an application acceleration company in the multi-platform games industry that engages in joint ventures, acquisitions and international opportunities. It now has two divisions. One is MediaPlay, targeting opportunities internationally and focused on joint venture efforts and larger projects, such as supplying TV channels with services. MediaPlay is an international multi-platform games publisher and developer acquired in mid-August by SWRM. The other division is Incubation and Acquisition Development (IAD), which is focused on the incubation program and direct acquisitions, as well as gaming opportunities, interactive development and e-commerce business solutions to enhance SWRM’s organic growth.

SWRM’s management team may be new, but it is very experienced in business management, the mobile games market, achieving joint ventures, licensing and aiding games developers as an incubator. Brewer, who joined SWRM last year, has served as managing director of Southbridge Advisory Group since 1990. Southbridge is a boutique firm focused on management services and M&A. John Rabbitt, SWRM’s CFO and director, has an extensive and diverse business background, having held positions at The Pillsbury Company and PepsiCo.

In addition, Chris Gray, president of the studios at MediaPlay, is a 30-year veteran of the video game industry. Steve Wall, president of publishing at MediaPlay, is a 23-year industry veteran who founded or co-founded five game companies and oversaw the launch of greater than 600 games.

“We want to get both divisions fully launched and out in market,” Brewer said in the interview. “We see a possibility, probability, and our managers are wanting to forecast for 2018 somewhere between $6 million and $7 million in revenue.”

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Proprietary biosynthesis process to produce cannabinoids
• Provisional patent application filed
• Cost-effective methodology to produce trace cannabinoids

If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don’t want a business that’s easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://dtn.fm/9al5F). Naturally, the Sage of Omaha was referring to an economic moat and not its tangible water-filled counterpart. One obvious way of constructing such an economic moat would be by registering a patent, which is exactly what InMed is planning to do. The company, which specializes in the research and development (R&D) of novel, cannabinoid-based drug therapies, has announced the filing of a provisional patent application for its proprietary biosynthesis process for the manufacture of cannabinoids that are identical to those found in nature (http://dtn.fm/I8g3M).

This filing is the first step in setting up defenses. Under U.S. patent law, a provisional patent application filed with the United States Patent and Trademark Office (USPTO) allows the filer to get a filing date and book a place in the queue. But, just as importantly, it affords protection for up to 12 months without filing a complete patent application. The provisional application may later be converted into a non-provisional one or be replaced by a regular patent application. The process in Canada, although not the same, is very similar.

To obtain protection outside North America, the Patent Cooperation Treaty (PCT) offers one streamlined route. The PCT procedure facilitates a patent application in all contracting states that are signatories with one filing, obviously a boon, since 145 sovereign states are members of the PCT. The PCT process allows the filing of an “international patent application,” which acts as an initial application for a patent in any member country. However, an “international patent application” never matures into an “international patent”. No such animal exists. A PCT filing simply reduces the burden of individual filings to contracting states and acts as a patent application to the contracting state in which the patent is meant to go into effect. Patents are issued by sovereign states and are always limited to national boundaries.

InMed’s provisional patent application will protect the biosynthesis process it has developed for the production of cannabinoids. In itself, biosynthetic production of chemicals is nothing new, but it really took off in 1978 after Genentech succeeded in modifying Escherichia-coli (E-coli) bacteria to produce synthetic insulin, a breakthrough credited with saving thousands of lives. Insulin is required by diabetics, whose bodies either do not produce the hormone or handle it inefficiently, in order to absorb glucose. In its absence, blood sugar increases to levels that may damage internal organs. Before biosynthesis, insulin was produced from the pancreas of pigs and cows in a costly, rather inhumane process.

InMed’s biosynthesis technology involves a process that can be applied to manufacture all the naturally occurring cannabinoids, through which the DNA of the cannabinoid to be produced is applied to Escherichia-coli (E-coli) bacteria. The E-coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate and multiply. This process combines the inherent safety and known efficacy of the natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process.

InMed’s biosynthesis methodology will likely be used to produce the less naturally occurring phytocannabinoids such as delta-8 tetrahydrocannabinol (Δ8 THC), cannabidivarin (CBDv), and tetrahydrocannabivarin (THCv), although, for the present, the company is not saying. Regardless of which cannabinoid castles InMed decides to build, they will all be protected by a sturdy economic moat.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board